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Mini-abstract  
The venous thromboembolism risk among anti-osteoporotics is unknown. In this primary care 
study, the risk with other bisphosphonates [1.05 (0.94-1.18), and 0.96 (0.78-1.18)], strontium 
[0.90 (0.61-1.34), and 1.19 (0.82-1.74)], in the UK and Spain respectively; and denosumab [1.77 
(0.25-12.66)], and teriparatide [1.27 (0.59-2.71)] in Spain, did not differ versus alendronate. 
 
 
Abstract  
Purpose/Introduction 
Most of the known adverse drug reactions described for anti-osteoporosis medication (AOM) 
have been described in studies comparing AOM users to non-users. We aimed to compare the 
risk of venous thromboembolism (VTE) amongst incident users of different AOM compared to 
alendronate (first line therapy).  
Methods 
Two cohort studies were performed using data from the UK (CPRD) and Spain (BIFAP) primary 
care records separately. All patients aged ≥50 years with at least 1 year of data available and a 
new prescription or dispensation of AOM (date for therapy initiation) during 2000-2014 
(CPRD), or 2001-2013 (BIFAP) were included. Users of raloxifene/bazedoxifene were excluded 
from both databases. Five exposure cohorts were identified according to first treatment: 
1.alendronate, 2.other bisphosphonates, 3.strontium ranelate, 4.denosumab, and 
5.teriparatide. Participants were followed from the day after therapy initiation to the earliest 
of: a treated VTE (cases), end of AOM treatment (defined by a refill gap of 180 days), switching 
to an alternative AOM, drop-out, death, or end of study period. Incidence rates of VTE were 
estimated by cohort. Adjusted Hazard ratios (HR; 95%CI) were estimated according to drug 
used.    
Results 
Overall, 2,035/159,209 (1.28%) in CPRD, and 401/83,334 (0.48%) in BIFAP had VTE. Compared 
to alendronate, adjusted HR of VTE were 1.05 (0.94-1.18), and 0.96 (0.78-1.18) for other 
bisphosphonates; and 0.90 (0.61-1.34), and 1.19 (0.82-1.74) for strontium in CPRD and BIFAP 
respectively; and 1.77 (0.25-12.66) for denosumab, and 1.27 (0.59-2.71) for teriparatide in 
BIFAP.  
Conclusions 
VTE risk during AO therapy did not differ by AOM drug use. Our data does not support an 
increased risk of VTE associated with strontium ranelate use in the community. 
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Introduction 
Strontium ranelate was approved in Europe in 2004 for the treatment of postmenopausal 
osteoporosis to reduce vertebral and hip fractures (1), and in 2012 for men at increased risk of 
fractures (2). Following a retrospective evaluation of clinical trials an increased risk of venous 
thromboembolism (VTE) was observed in strontium ranelate  arms compared to placebo (3). 
Thus, new contraindications for patients with a history of VTE or immobilization were added to 
strontium-containing medicines in 2012 (4), and additional risk minimization measures were 
imposed due to a suspected increase in cardiovascular risk in 2014, including contraindications 
for patients with history of ischaemic heart disease, peripheral arterial disease, 
cerebrovascular disease, or uncontrolled hypertension was established (5–8).  
Despite increasing evidence on the potentially thrombotic effects of strontium ranelate and 
selective estrogens receptor modulators (raloxifene and bazedoxifene), no data is to our 
knowledge available on the potential risk of VTE amongst users of other anti-osteoporosis 
medication (AOM). Increased risks of VTE (as for most of the known adverse drug reactions 
described for AOM) have been described in studies comparing AOM users to AOM-naïve 
patients. To what extent VTE risk is different amongst actual users of different AOM in a 
clinical practice setting is hence yet unknown.  
We therefore aimed to compare the risk of VTE amongst incident users of different AOM 
available in primary care settings in the UK and Spain (including alendronate, other oral 
bisphosphonates, strontium ranelate, denosumab and teriparatide) using alendronate (first 
line therapy) as a reference group.  
Methods 
Source of Data 
We obtained data from primary care outpatient records for the UK Clinical Practice Research 
Datalink (CPRD) and Spanish “Base de datos para la investigación Farmacoepidemiológica en 
Atención Primaria” (BIFAP).   
CPRD 
In the UK, the majority of CPRD (9) is linked to secondary care inpatient diagnoses and 
procedures, as coded in the Hospital Episodes Statistics (HES) (10). CPRD comprises 
computerized records of all clinical and referral events in both primary and secondary care, in 
addition to comprehensive demographic information. Data include medication prescriptions 
by general practitioners (GPs) using the British National Formulary (11), clinical events 
recorded using READ codes (12,13), referrals, and hospital admissions with their major 
outcomes in a sample of >7 million patients, chosen to be representative of the wider UK 
population. HES is the national statistical data warehouse of the care provided by NHS 
hospitals, and it stores data on diagnoses and procedures carried out during hospital 
admission for the whole of England.  
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BIFAP 
In Spain, the BIFAP database (14) is a longitudinal population-based database of anonymized 
electronic medical records of primary care practitioners and paediatricians (PCP) from 9 
different regions in Spain (9). BIFAP is fully financed by the Spanish Agency on Medicines and 
Medical Devices (AEMPS), belonging to the Department of Health. The database includes 
information of 2324 physicians (84% general practitioners and 15% paediatricians), on patient 
demographics, clinical events (coded through ICPC medical terms dictionary, free text notes, 
specialist referrals and laboratory test results of around 4 million patients (19 million patient-
years) covering around 8.6% of the Spanish population at the time this study was performed. 
Prescriptions are automatically recorded in BIFAP at consultation. 
The study protocol was approved by the UK Independent Scientific Advisory Committee ISAC 
(REF 14_110R) and BIFAP Scientific Committee (Number 02_2015). 
Study Design 
Two cohort studies were performed using data from CPRD and BIFAP separately.  
Study population 
All patients aged ≥50 years with a new prescription or dispensation of AOM (date for therapy 
initiation) during each database study period, i.e. 2000-2014 (CPRD), or 2001-2013 (BIFAP) and 
at least 1 year of available recorded data before therapy initiation were included. Patients with 
a prescription or dispensation of AOM recorded during the year before that therapy initiation 
were excluded (considered as prevalent users). Users of raloxifene and bazedoxifene were also 
excluded as these were formally contraindicated for patients with a history of VTE and warned 
for patients at VTE risk from marketing authorization (15). 
Treatment episodes and exposure definition 
The study population was divided in five exposure cohorts according to AOM of first treatment 
episode: 1. alendronate (Anatomical Therapeutic Chemical (ATC) classification: M05BA04 and 
M05BB03), 2. other oral bisphosphonates (etidronate [M05BA01], ibandronate [M05BA06], 
risedronate [M05BA07], clodronate [M05BA02] and tiludronate [M05BA05]; these two last 
were only available in Spain); 3. strontium ranelate (M05BX03), 4. denosumab (M05BX04), and 
5. teriparatide (H05AA02). 
Treatment episodes were periods of continuous use, i.e. with no gaps of over 180 days 
between repeat prescriptions. Such episodes were defined as a series of subsequent 
prescriptions durations for each AOM (into each cohort), independent of ATC/BNF code 
switching and change of dose within each cohort. Figure 1. Treatment episodes were 
constructed according to the method 1 by Gardarsdottir et al (16) and similarly for the 
reference and the comparison exposure cohorts.   
Defined daily dose (DDD) assigned by the WHO were assumed by default of the AOM studied. 
Duration of a prescription was based on the calculated prescribed DDD. The theoretical end 
date of each prescription equaled the prescription/dispensing date plus the duration of drug 
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use calculated through DDD prescribed. In case a subsequent prescription with the same drug 
was collected before the theoretical end date of a previous prescription the number of 
overlapping days/DDD was disregarded assuming that overlapping days compensate gaps 
between prescriptions. 
If the subsequent prescription within the same treatment episode included another drug type 
into same cohort, the patient was considered to have switched therapy and the remaining 
tablet days from the prior prescription was disregarded. 
A new treatment episode was considered when an interval of 180 days or more was present 
between the theoretical end date of a prescription and the prescription date of the 
subsequent prescription for the same patient. Only first treatment episode was assessed in 
this study, as well as the 180 days afterwards. Sensitivity analysis using 90 and 30 days of 
intervals were also performed. 
Case ascertainment 
Participants from exposure cohorts were followed from the day after therapy initiation to the 
earliest of the following: a record of VTE diagnosis with at least 1 prescription of heparin or 
oral anticoagulant recorded during the 60 days after VTE (case definition), 180 days after the 
end of the first AOM treatment episode (end of the supply of the last prescription before a gap 
of 180 days), switching to an alternative cohort exposure, lost to follow up, death or end of 
study period. Annex I shows READ, and ICPC codes for VTE diagnosis identification in the 
contributing databases. 
Potential confounders  
Risk factors for VTE based on NICE guidelines (17) and other factors related to the AOM were 
collected as present or not, anytime before therapy initiation (unless otherwise mentioned 
afterwards), as potential confounders of the studied association. Confounders included age, 
sex, history of VTE, venous insufficiency or phlebitis, recent fractures (recorded during 2 
months before therapy initiation), hormone replacement therapy (HRT; prescribed during the 
year before therapy initiation), Charlson index (when available, i.e. CPRD), cancer and 
peripheral arterial disease (in BIFAP, since Charlson index was not available for ICPC 
classification). BMI (kg/m2) and current smoking (yes/no) were collected as recorded during 
the year of therapy initiation. Information about the use of other AOM (i.e. parathyroid  
hormone, calcitonin, and elcatonin), calcium-vitamin D supplements, glucocorticoids, heparins, 
and oral anticoagulant drugs were also collected for description.  
Statistical methods 
Incidence rate (IR; 95%CI) of treated VTE per 1,000 person-years under first AOM were 
estimated by exposure cohort, and age.  
Hazard ratios (HR) and 95% confidence intervals (95%CI) for treated VTE were computed for 
each exposure cohort compared to alendronate (reference group) using Cox regression after 
adjustment for potential confounders listed in tables 2 and 3 footnotes. Potential effect 
modification and p for interaction (p-int) by calendar period (pre-2011 vs. 2011 onwards), sex 
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and age categories (50-59, 60-69, 70-79, and ≥80 years) were evaluated. When p-int was 
below 0.2 HR were calculated for each strata. 
Multiple imputation  was performed to account for missing BMI and smoking data. Imputed 
BMI and smoking values were assigned after conditioning to variables included in the 
multivariable Cox model (i.e. type of cohort exposure, outcome, the Nelson-Aalen estimate of 
the survival model, and all the confounders listed above), and the identified predictors of both 
missingness and values of BMI and current smoking respectively (18). Fifteen datasets were 
imputed and combined using Rubin’s rules. 
Patient involvement 
No patient/s or public representatives have been involved as part of this work. 
Results 
The study populations were made of 159,209 and 83,334 new users of AOM in the UK (CPRD) 
and Spanish (BIFAP) primary care settings. The majority were women 80% and 90%, while 
alendronate constituted 79.8% and 43.4% of the study population in CPRD and BIFAP, 
respectively. Baseline characteristics according to exposure cohort are reported in Table 1.  
In CPRD, patients on other bisphosphonates did not show differences in baseline 
characteristics compared to alendronate users, while users of strontium ranelate were older 
(56.7% vs. 31.7% were ≥80 years), and had a higher prevalence of recent fractures (16.2% vs. 
6.2%), and calcium-D supplementation (35.6% vs. 24.6%), but a lower proportion of 
glucocorticoids use (26.9% vs. 40.8%). History of VTE was more commonly present in the 
denosumab cohort (10.3% versus 5.2% in alendronate cohort). As there were only 7 patients 
prescribed teriparatide in CPRD comparisons are poor. In BIFAP, users of strontium ranelate 
had higher prevalence of venous insufficiency or phlebitis (22.1% vs. 19.2%), recent fractures 
(10.3% vs. 7.8%), and heparin use (15.4% vs. 11.9%) than alendronate users. Users of 
denosumab or teriparatide were older than alendronate users (27.0% and 27.8% vs. 15.6% 
aged ≥80y), and had a higher prevalence of other AOM (13.3% and 14.8%, vs. 7.5%), calcium-D 
(65.9% and 42.10% vs. 34.0%), glucocorticoids (32.1% and 28.3% vs. 18.0%), heparin (18.1% 
and 26.7% vs. 11.9%) and oral anticoagulant drugs (5.1% and 10.5% vs. 4.9%). History of VTE 
was higher in teriparatide users (3.1%) than alendronate users (1.4%).  
The time to follow-up and incidence rates of VTE by AOM cohort and database are shown in 
Table 2.  
Overall, 2035 (CPRD), and 401 (BIFAP) VTE cases were detected during the index (first) 
treatment episode. Crude IR of VTE were 4.84 (95%CI: 4.61-5.08) and 2.36 (95%CI: 2.04-2.72) 
per 1,000 person-years at risk (PYAR) for alendronate; 5.08 (95%CI: 4.59-5.63), and 2.21 
(95%CI: 1.91-2.56) for other biphosphonates; 5.06 (95%CI: 3.42-7.48) and 2.89 (95%CI: 2.04-
4.09) for strontium ranelate; and 24.06 (3.39-170.8) and 5.16 (95%CI: 0.73-36.60) for 
denosumab in CPRD and BIFAP participants respectively. IR of VTE among teriparatide users 
was 4.67 (95%CI: 2.22-9.79) in BIFAP.  IR of VTE increased with age in all AOM cohorts. 
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The HR of VTE associated to each AOM is shown in Table 2 (results stratified by database). 
Compared to alendronate (reference group), adjusted HRs were 1.05 (0.94-1.18) and 0.96 
(0.78-1.18) for other biphosphonates; 0.90 (0.61-1.34), and 1.19 (0.82-1.74) for strontium 
ranelate; and 3.47 (0.49-24.7) and 1.77 (0.25-12.66) for denosumab in CPRD and BIFAP 
respectively; and 1.27 (0.59-2.71) for teriparatide in BIFAP. After adjusting by heparin and oral 
anticoagulant drugs none of the HR changed significantly vs. main model for any of the drugs 
studied in BIFAP or CPRD. 
Figure 2 shows the HR observed in main analysis and sensitivity analysis using 90 and 30 days 
of gaps. In CPRD, the risk associated with strontium ranelate was slightly higher in the main 
analysis (HR: 0.90; 95%CI: 0.61-1.34) than in the sensitivity analyses (HR: 0.83 (0.53-1.31) and 
0.86 (0.48-1.52), for 90 and 30 days intervals respectively). The opposite was true for 
denosumab (HR: 3.91 (0.55-27.81) and 5.03 (0.71-35.81) for 90 and 30 days intervals 
respectively. Risk associated with other bisphosphonates did not change with the different 
intervals, being 1.05 (0.92-1.18) for 90 days interval and 1.06 (0.90-1.24) for 30 days interval. 
In BIFAP, the risk of VTE associated to all exposure cohort versus alendronate was diluted with 
the increase in the interval, i.e. for other bisphosphonates HR was 1.04 (0.77-1.41) for 30 days 
interval and 0.98 (0.78-1.24) for 90 days interval, for denosumab 2.02 (0.28-14.61) and 1.89 
(0.26-13.6), for teriparatide 1.48 (0.59-3.68) and 1.32 (0.58-3.00), and for strontium ranelate 
1.50 (0.90-2.51) and 1.44 (0.96-2.15) for 90 and 30 days intervals respectively. 
In CPRD and BIFAP, overall patients treated with any AOM from 2011 onwards seem to be 
slightly older compared to those initiating AOM before 2011 (74.5 vs. 73.3 in CPRD and 69.8y 
vs. 68.4y in BIFAP), and more frequently had a history of recent fractures (10.1% vs. 5.5% in 
CPRD and 11.8% vs.7.8% in BIFAP), previous use of calcium-vitamin-D (27.1% vs. 25.1% in CPRD 
and 37.8% vs. 35.1% in BIFAP), glucocorticoids (42.4% vs. 40.3% in CPRD and 31.3% vs. 18.4% 
in BIFAP), heparin (3.0% vs. 0.8% in CPRD and 18.8% vs. 12.2% in BIFAP) and oral anticoagulant 
drugs (10.1% vs. 8.1% in CPRD and 7.6% vs. 4.7% in BIFAP) and less use of HRT (1.4% vs. 5.5% 
in CPRD and 0.6% vs. 3.0% in BIFAP). Additionally, in BIFAP, patients treated with any AOM 
from 2011 onwards seem to more frequently have a history of VTE (2.2% vs. 1.3% specially 
bisphosphonates), cancer (14.7% vs. 9.8%), peripheral arterial disease (1.9% vs. 1.1%) and vein 
insufficiency or phlebitis (24.3% vs. 19.6%). These overall data are not reported in tables. 
Baseline characteristics of patients initiating the therapy before 2011, and from 2011 onwards 
by exposure cohort are reported in Table 3 of Annex I. In particular for strontium ranelate, the 
crude prevalence of recent fractures was much higher among patients initiating therapy from 
2011 onwards than before 2011 (23.3% vs. 14.2% in CPRD, and 18.8% vs. 9.1% in BIFAP, 
respectively), as was the previous use of anticoagulant drugs (3.4% vs. 1.0% used heparin and 
8.8% vs. 8.2% used oral anticoagulants in CPRD; and 23.5% vs. 14.2% used heparin and 7.5% 
vs. 4.1% used oral anticoagulants from 2011 onwards and before 2011, respectively). The VTE 
history seemed similar among patients initiating therapy from 2011 onwards than before 2011 
(4.6% vs. 5.4% in CPRD, and 1.6% vs. 1.2% in BIFAP, respectively). 
Table 3 shows the HR by calendar periods (stratified as before 2011, and from 2011 onwards), 
sex and age for CPRD and BIFAP.  
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Borderline effect modification was suggested among calendar periods in BIFAP (p-int=0.08), 
while no effect modification in CPRD (p-int = 0.99). Regarding sex strata, borderline effect 
modification was suggested in CPRD (p-int=0.19), while no effect modification in BIFAP (p-int = 
0.83). Regarding age categories, no effect modification was suggested in BIFAP (p-int=0.21), or 
in CPRD (p-int=0.51). Therefore, similar to overall analysis, non-statistically significant 
differences in risk (compared with alendronate) were found in calendar periods,  either sex, or 
age strata.  
Discussion 
In the current study, VTE risk during first AOM treatment period did not differ by type of AOM 
prescribed in the UK or Spain primary care settings. In particular, our data does not support an 
increased risk of VTE associated with strontium ranelate versus alendronate. No association 
was observed, irrespective of calendar period, sex, or length of different risk windows for VTE 
evaluation as used in sensitivity analyses.  
Strontium ranelate was approved in Europe in 2004 for treatment of postmenopausal 
osteoporosis to reduce vertebral and hip fractures (1), and in 2012 for men at increased risk of 
fractures (2). The risk of VTE was identified in clinical trials, and warnings were included in the 
product information. In 2011 a manuscript reported that 28% of the 93 VTE spontaneously 
reported with strontium ranelate in France had VTE risk factors (mainly VTE history and 
immobilization) (19). Thus, a formal review by the CHMP was released in October 2011 (20). 
After retrospective evaluation of clinical trials results (3803 strontium versus 3769 placebo) a 
non-significant 37% increased risk of VTE versus placebo was observed (95%CI: 0.99-1.89), 
being higher (87% increased risk; 95%CI: 1.06-3.31) among patients aged 80 years (3). The 
evaluation of the epidemiological studies and post-marketing surveillance showed that a 
history of VTE or immobilization were important risk factors for VTE, so in order to minimise 
the risk of VTE in these patients the existing warnings were upgraded to a contraindication for 
strontium-containing medicines in 2012 (4).  
We did not formally assess whether the release of that safety review and further 
contraindication affected the profile of patient treated with SR in the studied populations. At a 
glance, the crude prevalence of VTE risk factors was not lower among patients who initiated 
strontium ranelate therapy from 2011 onwards versus before 2011. In particular, the recent 
fractures (proxy for immobilization) and use of anticoagulant drugs was much higher among 
patients initiating therapy from 2011 onwards than before 2011, while the VTE history seemed 
similar in both periods. The same was observed among patients treated with bisphosphonates 
from 2011 onwards. This, together with the older age and less use of HRT from 2011 onwards, 
may suggest a higher baseline risk of VTE among overall patients treated with AOM in the 
latter years of the study. These data must be interpreted with caution since low population 
sizes from 2011 was analyzed. Formal studies using big populations sizes after contraindication 
in 2012 and restrictions in 2014 confirmed a decrease of VTE risk factors after the minimization 
measures disseminated to reduce the cardiovascular risk in 2014 among patients treated with 
strontium ranelate (21). 
Nonetheless, in the current study the risk of VTE associated with strontium ranelate was not 
different from alendronate, both before or from 2011 onwards.  
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The increased risk of VTE previously reported has been described in comparison to AOM-naïve 
patients, in which the risk of VTE is higher among SR or alendronate users than non-
osteoporotic patients in an observational study in CPRD (23). However, that risk did not differ 
by type of drug among patients under anti-osteoporosis therapy (23), nor was it higher during 
exposure versus non-exposure periods in patients with VTE that were ever exposed to SR (24). 
These studies are in agreement with our finding of no statistically significant differences 
among the various types of AOM investigated. Recently, no difference in the risk of VTE 
between strontium ranelate and alendronate has been observed among patients without 
contraindications in a multi-database study (22). 
In the current observational study, we tried to avoid confounding by indication by comparing 
patients with the same indication, i.e. osteoporosis or prescription of an AOM. In order to 
control by other potential confounders, baseline morbidity and medication were measured 
and revealed a pattern of older patients among the strontium than alendronate cohort, with 
more prevalence of calcium-D in CPRD and recent fractures (in both databases). Small 
differences of adjusted versus crude risk estimates were observed, but it cannot be ruled out 
that unmeasured confounders, such as severity of osteoporosis, might still be playing a role in 
the risk estimation. 
Regarding biological plausibility, no clear pharmacological mechanism which could link 
strontium ranelate to thromboembolism has been evidenced. In clinical trials, an increase in 
Factor VIII level and a concomitant decrease in activated partial thromboplastin time were 
observed, which tend to a more thrombotic state. Nevertheless, the clinical relevance of these 
changes is not clear, especially for older patients (4).  
Since no pharmacological mechanism for triggering VTE was known for SR, we arbitrarily 
selected a long risk window of 180 days, in addition to performing sensitivity analyses using 
two shorter different time intervals (i.e. 30 and 90 days) in order to understand the duration of 
potential thrombosis effect of each drug type and explore the potential mechanism. No risk 
associated with any AOM versus alendronate was observed in sensitivity analyses although 
results were heterogeneous in CPRD and BIFAP. The risk of VTE with SR decreased as the 
interval was reduced from 180 days to 30 days in CPRD, and the opposite was true in BIFAP 
where the risk for all AOM was stronger with the reduction of interval (suggesting a short-term 
effect).  
It may happen that the comparison of type of drugs would have required the use of different 
risk windows according to the expected pharmacological mechanism (and potentially different 
duration of thrombosis effect). However, no VTE pharmacological mechanism was known for 
the studied drugs so similar intervals were utilized for all exposures studied. 
The strengths of the current study include the large number of patients within exposure 
cohorts for bisphosphonates and strontium ranelate and the diversity of patients studied, in 
particular elderly and more unwell patients which are not represented in a RCT setting. Our 
study is representative of the primary care treatment routine. The external validity or data was 
also showed by the similar incidence of VTE observed in CPRD (5.6 per 1000 patient-years) 
with the one published for patients dispensed with SR during the first 12 months after starting 
treatment in the UK (6.24 per 1000 patient-years; mean age was 73.3 years [SD 11.45])(25). 
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Unfortunately, no external source is available to validate incidence of VTE in SR users in Spain. 
But comparing BIFAP with UK data, the lower incidence in BIFAP (2.8 per 1000 patient-years) 
may be the expected after considering the five time lower prevalence of history of VTE in 
BIFAP versus CPRD.  
Other strengths include the comparison among patients prescribed with any AOM (hence 
avoiding confounding by indication), the new estimation of VTE risk in Spanish population 
treated with AOM, and the similar methodological protocol allowing for comparison of results 
from two databases and countries. 
Some limitations may be mentioned. Confounding by severity of osteoporosis could not be 
ruled out. Also, we did not validate compliance to AOM treatment against physician or patient. 
One-year cessation of AOM treatment has been reported between 51% and 61% in the 
literature (26–28). However, we only studied the first period of continuous re-fill prescriptions, 
and a similar method to build treatment periods for all the compared exposures, expecting to 
minimize the potential impact of differential compliance (and other potential source of 
misclassification derived from the assumption taken to build the treatment episodes) 
according to type of AOM compared.   
Furthermore, we did not validate the recorded diagnosis of VTE nor its date. However, we 
selected patients with anticoagulant treatment recorded on VTE recorded date or 60 days 
after in order to increase the predictive value of the episodes and their dates. Also, a high 
positive predictive value of DVT or PE records in CPRD (84-94%) was estimated previously in an 
information validation against hospital investigations, a death certificate, or physician (29,30). 
Also, in a post-hoc manual review of the clinical profiles of the 401 patients with a recorded 
treated VTE in BIFAP, we observed that 2.2% of them (N=9) had a discharge or referral letter 
refuting the VTE episode. After excluding those non-cases, the final interpretation of the study 
did not change, i.e. no significant increased risk was associated with any AOM versus 
alendronate. The indication of treatment was not evaluated.  
In conclusion, after assessment of the clinical information recorded during the first continuous 
treatment episode of other oral bisphosphonates, strontium ranelate, teriparatide, or 
denosumab (ranging a median duration of 7 months to 1.74 years) of around 240,000 patients 
attending their primary care physician in Spain and the UK, the risk of VTE did not differ versus 
alendronate. This result was irrespective of sex, calendar period, or length of risk windows 
used. 
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Figure 1. Treatment episodes construction. 
 
 
 
 
 
Figure 1 footnote: Rx: prescription duration; 180d: 180 days 
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Figure 2. Risk of VTE associated to each AOM versus alendronate (Hazard Ratio) using 90 and 30 days as 
a gap (Sensitivity analysis), in CPRD and BIFAP.  
 
 
 
 
Figure 2 footnote: CPRD: Clinical Practice Research Datalink; BIFAP: Base de datos para la investigación 
Farmacoepidemiológica en Atención Primaria; O. Bisphosphonates: Other oral Bisphosphonates; HR: Hazard ratio; 
CI: 95% Confidence Interval; 180d/90d/30d: days of interval between prescriptions durations in main (180 days) 
and sensitivity analysis (90 and 30 days) 
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